Roivant Sciences Ltd
ROIV · NASDAQ
+$0.31 today
- Mkt cap $21.61B
- P/E 0.0
- Day $29.87 – $30.61
Confidence
High conviction
The read
Roivant Sciences shares rose 4.6% post-earnings despite no reported EPS, supported by strong analyst buy ratings
Roivant Sciences reported Q1 2026 results without disclosed EPS, with shares gaining 4.6% on June 4. Analysts maintain a buy consensus with a $36.53 average target, reflecting confidence despite weak recent revenue trends. Institutional ownership remains high at 73%, while forward EPS growth is projected at 21.8%.
Confidence note: Analysis based on strong market reaction, analyst consensus, and institutional ownership despite missing EPS data; limited by absence of explicit guidance or reported earnings.
What happened
Earnings print
Guidance
Price reaction
Street narrative
So what
What changed
What the market is pricing
Fundamental takeaway
Next 30–90 days
Positive clinical trial or regulatory news drives share price above analyst targets.
- boltAnnouncement of favorable clinical trial results
- boltRegulatory approval or positive update
Shares trade sideways with modest volatility as market awaits clearer earnings details or catalysts.
- boltStable operational updates
- boltNo major news flow
Emerging pipeline risks or competitive pressures lead to share price decline despite analyst optimism.
- boltDisclosure of pipeline setbacks
- boltIncreased competitive threats
What to do
If you hold it
If you're watching
Keep on your radar
- Clinical trial results or regulatory announcements within next 90 days
- Share price relative to 50-day SMA (~$28.83)
- Institutional ownership changes from current 73%
- Analyst rating revisions or target price updates